Rob is the cancer researcher at Peter Mac (since 1995). His PhD in Biochemistry was gained the University of Queensland based on my research in melanoma genetics at the Queensland Institute for Medical Research. He did post-doctoral training at Memorial Sloan Kettering Cancer Centre New York, NY and the Ludwig Institute, Melbourne and was a NHMRC Research Fellow to 2016. His research interest’s span from stem cells and GI and breast cancer and his group has as strong clinical engagement in trials (seven current studies). These are focused on immunotherapy [aMYB (NCT03287427, aKRASmutant (NCT02933944) and chemoradiotherapy (NCT03299660) all combined with checkpoint inhibition blockade] and inflammation during cancer surgery in patient with colorectal and adenoid cystic carcinoma. He is perhaps best known for his research on the oncoprotein, MYB and colon cancer, breast cancer and adenoid cystic carcinoma. The lab has five surgeons conducting PhDs being undertaken as part of the GI cancer program where we have develop a suite of functional immune assays using patient derived tumoroids and tumor infiltrating lymphocytes that support the evaluation of the clinical trials.